文献速递妇科肿瘤骨软组织肉瘤与黑色素瘤

奥拉帕利联合替莫唑胺治疗晚期子宫平滑肌肉瘤的II期研究(NCI方案10250)

Phase II Study of Olaparib and Temozolomide for Advanced Uterine Leiomyosarcoma (NCI Protocol 10250).
PubMed 文献 · J Clin Oncol · 2023-07-19

NCI方案10250是一项单臂、开放标签、多中心II期研究,评估奥拉帕利联合替莫唑胺在晚期子宫平滑肌肉瘤中的疗效。22例可评估患者中,6个月内最佳客观缓解率为23%(5/22),总客观缓解率为27%(6/22),中位无进展生存期为6.9个月(95%CI 5.4个月至不可估计)。研究达到预设主要终点,在经治晚期患者中提供有意义的临床获益。

要点

  • 奥拉帕利联合替莫唑胺达到预设主要终点,6个月内最佳ORR为23%(5/22)。
  • 中位PFS为6.9个月(95%CI 5.4个月至不可估计)。
  • 3/4级中性粒细胞减少75%,血小板减少32%,经剂量调整可管理。

核心结论

  • 奥拉帕利联合替莫唑胺达到预设主要终点,在晚期经治子宫平滑肌肉瘤患者中提供有意义的临床获益。

研究设计与样本

  • NCI方案10250是一项单臂、开放标签、多中心II期研究,评估奥拉帕利联合替莫唑胺在晚期子宫平滑肌肉瘤中的疗效。
  • 患者接受替莫唑胺75 mg/m2口服每日一次联合奥拉帕利200 mg口服每日两次,均在第1-7天给药,21天为一周期。
  • 主要终点为6个月内最佳客观缓解率,采用一阶段二项设计,若22例中≥5例缓解则认为治疗有前景(把握度93%;α=.06)。
  • 所有患者接受配对活检,行全外显子测序(WES)/RNAseq和RAD51聚焦形成试验评估。
  • 22例患者可评估,中位年龄55岁,59%接受过三线及以上既往治疗。

主要发现

  • 6个月内最佳ORR为23%(5/22),总ORR为27%(6/22)。
  • 中位无进展生存期(mPFS)为6.9个月(95%CI 5.4个月至不可估计)。
  • 血液学毒性常见:3/4级中性粒细胞减少75%,血小板减少32%,经剂量调整可管理。
  • WES显示16例肿瘤中5例(31%)携带有害同源重组基因改变,RAD51试验显示18例中9例(50%)为同源重组缺陷。
  • 探索性分析显示,RAD51试验中同源重组缺陷患者较同源重组功能正常患者mPFS延长(11.2个月 vs 5.4个月,P=.05)。

关键数值与推荐

  • 6个月内最佳客观缓解率:23%(5/22)。
  • 总客观缓解率:27%(6/22)。
  • 中位无进展生存期:6.9个月(95%CI 5.4个月至不可估计)。
  • 3/4级中性粒细胞减少75%,3/4级血小板减少32%。
  • WES检出有害同源重组基因改变:5/16(31%);RAD51试验检出同源重组缺陷:9/18(50%)。

临床怎么用

  • 奥拉帕利联合替莫唑胺达到预设主要终点,在晚期经治子宫平滑肌肉瘤患者中提供有意义的临床获益。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Uterine leiomyosarcoma (uLMS) is an aggressive subtype of soft-tissue sarcoma with frequent metastatic relapse after curative surgery. Chemotherapy provides limited benefit for advanced disease. Multiomics profiling studies have identified homologous recombination deficiency in uLMS. In preclinical studies where olaparib and temozolomide provided modest activity, the combination was highly effective for inhibiting uLMS tumor growth. PATIENTS AND METHODS: NCI Protocol 10250 is a single-arm, open-label, multicenter, phase II study evaluating olaparib and temozolomide in advanced uLMS. Patients with progression on ≥1 prior line received temozolomide 75 mg/m2 orally once daily with olaparib 200 mg orally twice a day both on days 1-7 in 21-day cycles. The primary end point was the best objective response rate (ORR) within 6 months. A one-stage binomial design was used. If ≥5 of 22 responded, the treatment would be considered promising (93% power; α = .06). All patients underwent paired biopsies that were evaluated with whole-exome sequencing (WES)/RNAseq and a RAD51 foci formation assay. RESULTS: Twenty-two patients were evaluable. The median age was 55 years, and 59% had received three or more prior lines. Best ORR within 6 months was 23% (5 of 22). The overall ORR was 27% (6 of 22). The median progression-free survival (mPFS) was 6.9 months (95% CI, 5.4 months to not estimable). Hematologic toxicity was common (grade 3/4 neutropenia: 75%; thrombocytopenia: 32%) but manageable with dose modification. Five of 16 (31%) of tumors contained a deleterious homologous recombination gene alteration by WES, and 9 of 18 (50%) were homologous recombination-deficient by the RAD51 assay. In an exploratory analysis, mPFS was prolonged for patients with homologous recombination-deficient versus homologous recombination-proficient tumors (11.2 v 5.4 months, P = .05) by RAD51. CONCLUSION: Olaparib and temozolomide met the prespecified primary end point and provided meaningful clinical benefit in patients with advanced, pretreated uLMS.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Ingham M, Allred JB, Chen L, et al. Phase II Study of Olaparib and Temozolomide for Advanced Uterine Leiomyosarcoma (NCI Protocol 10250). J Clin Oncol. 2023. PMID: 37467452. doi:10.1200/JCO.23.00402

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。